Medicus Pharma Ltd. (MDCX)
| Market Cap | 34.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.75M |
| Shares Out | 25.11M |
| EPS (ttm) | -2.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 331,426 |
| Open | 1.370 |
| Previous Close | 1.340 |
| Day's Range | 1.300 - 1.370 |
| 52-Week Range | 1.280 - 8.940 |
| Beta | -1.73 |
| Analysts | Strong Buy |
| Price Target | 23.50 (+1,615.33%) |
| Earnings Date | Feb 22, 2026 |
About MDCX
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MDCX stock is "Strong Buy." The 12-month stock price target is $23.5, which is an increase of 1,615.33% from the latest price.
News
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing ...
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
Amendment reduces and simplifies royalty structure on Teverelix ® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix ® as a first in class market product ...
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical deve...
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women
PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical deve...
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development strategy, and regulatory optionality The Comp...
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute uri...
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"),...
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025 PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 1, 2025 / Medicus...
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
November is Men's Health Awareness Month, a time to spotlight the latest medical breakthroughs that are transforming how we detect and treat cancer in men.
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access...
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire...
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM PHILADELPHIA, PA / ACCESS Newswire / No...
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) le...
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) le...
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
CLEVELAND CLINIC ABU DHABI (CCAD) IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the...
The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets
BRISTOL, TN / ACCESS Newswire / October 14, 2025 / Most biotech stories collapse on a single product failure. Medicus Pharma Ltd (NASDAQ:MDCX) built three distinct shots at blockbuster markets.
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (...
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION The Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai" PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7,...
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays (D-MN...
Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)
Dallas, Texas--(Newsfile Corp. - September 24, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX): Stonegate Capital Partners initiates their coverage on Medicus Pharma Ltd.
Medicus Pharma Ltd. To Present at Brookline Capital Markets
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, ...
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV r...
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus"...
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 b...